Comparing Liposomal Bupivacaine and Ropivacaine for Pain Relief After Laparoscopic Gallbladder Surgery Randomized Study Using Transversus Abdominis Plane Block

What this Trial Is About

Researchers are evaluating the pain relief effectiveness of liposomal bupivacaine compared to ropivacaine when used for transversus abdominis plane TAP block in patients undergoing laparoscopic gallbladder removal surgery. This randomized, single-blind, parallel-group clinical trial focuses on improving postoperative pain management. The primary measure is the dynamic pain score 24 hours after surgery, with additional assessments of recovery quality, analgesic use, and complications over time. Participants will be randomly assigned to receive either liposomal bupivacaine or standard-dose ropivacaine administered via ultrasound-guided TAP block after surgery. Both groups will receive routine clinical care during their hospital stay. The study includes follow-up assessments up to three months after surgery to monitor the development of chronic post-surgical pain. During the study, participants will have their pain levels measured at 24, 48, and 72 hours after surgery, along with evaluations of recovery quality using the QoR-15 scale. Researchers will track the time until additional pain medication is needed, total pain medication used, gastrointestinal recovery, hospital stay length, and any adverse events. Follow-up visits will assess longer-term pain outcomes, with the entire study lasting up to three months after surgery.

Efficacy of Liposomal Bupivacaine for Transversus Abdominis Plane Block